open access

Vol 14, No 1 (2010)
Prace oryginalne
Published online: 2010-04-27
Get Citation

Evaluation of hypotensive effect of telmisartan and telmisartan with hydrochlorothiazide in ambulatory blood pressure monitoring

Paweł Uruski, Katarzyna Kostka-Jeziorny, Radosław Szczęch, Andrzej Tykarski
Nadciśnienie tętnicze 2010;14(1):74-82.

open access

Vol 14, No 1 (2010)
Prace oryginalne
Published online: 2010-04-27

Abstract

Background Arterial hypertension is known, independent risk factor of cardiovascular disease. Elevated values of blood pressure (BP) increase cardiovascular mortality and are related to higher risk of myocardial infarction, stroke and kidney failure. It was observed that myocardial infarction and stroke occur more often in the early morning hours. That’s way BP should be controlled through out the whole day and especially in the morning hours. The aim of the study was to evaluate the twenty-four-hour efficacy and safety of telmisartan and telmisartan with hydrochlorothiazide (HCTZ) in treatment of arterial hypertension in clinical practice, in ambulatory patients, and especially to evaluate if combined therapy reveals additionally benefits in control of BP in the morning hours.
Material and methods A total of 320 patients in age above 18 years, with untreated, primary hypertension of I or II degree were recruited to the study. Telmisartan in dose of 40 mg or 80 mg or telmisartan with HCTZ (telmisartan 80 mg/ /HCTZ 12.5 mg) were prescribed to the patients. The study group was observed for 8 weeks. Office BP measurements and ABPM were performed.
Results During the study significant decrease of BP in ABPM in the morning hours (mean SBP 22.21 ± 11.11 mm Hg, mean DBP 11.62 ± 10.06 mm Hg) and significant decrease of office SBP and DBP measurements were observed.
Conclusion Telmisartan administered in monotherapy and as well as in combined therapy was very well tolerated by the patients, through out the whole study.

Abstract

Background Arterial hypertension is known, independent risk factor of cardiovascular disease. Elevated values of blood pressure (BP) increase cardiovascular mortality and are related to higher risk of myocardial infarction, stroke and kidney failure. It was observed that myocardial infarction and stroke occur more often in the early morning hours. That’s way BP should be controlled through out the whole day and especially in the morning hours. The aim of the study was to evaluate the twenty-four-hour efficacy and safety of telmisartan and telmisartan with hydrochlorothiazide (HCTZ) in treatment of arterial hypertension in clinical practice, in ambulatory patients, and especially to evaluate if combined therapy reveals additionally benefits in control of BP in the morning hours.
Material and methods A total of 320 patients in age above 18 years, with untreated, primary hypertension of I or II degree were recruited to the study. Telmisartan in dose of 40 mg or 80 mg or telmisartan with HCTZ (telmisartan 80 mg/ /HCTZ 12.5 mg) were prescribed to the patients. The study group was observed for 8 weeks. Office BP measurements and ABPM were performed.
Results During the study significant decrease of BP in ABPM in the morning hours (mean SBP 22.21 ± 11.11 mm Hg, mean DBP 11.62 ± 10.06 mm Hg) and significant decrease of office SBP and DBP measurements were observed.
Conclusion Telmisartan administered in monotherapy and as well as in combined therapy was very well tolerated by the patients, through out the whole study.
Get Citation

Keywords

arterial hypertension; ABPM; telmisartan; hydrochlorothiazide; combined therapy

About this article
Title

Evaluation of hypotensive effect of telmisartan and telmisartan with hydrochlorothiazide in ambulatory blood pressure monitoring

Journal

Arterial Hypertension

Issue

Vol 14, No 1 (2010)

Pages

74-82

Published online

2010-04-27

Bibliographic record

Nadciśnienie tętnicze 2010;14(1):74-82.

Keywords

arterial hypertension
ABPM
telmisartan
hydrochlorothiazide
combined therapy

Authors

Paweł Uruski
Katarzyna Kostka-Jeziorny
Radosław Szczęch
Andrzej Tykarski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl